Key Moments
- Johnson & Johnson (NYSE:JNJ) advanced 1.3% to $268.96 in premarket trading on Monday.
- Apollo Global Management (NYSE:APO) has been in talks to acquire J&J’s orthopedics division in a potential deal valued at nearly $20 billion, according to a report.
- The orthopedics business generated $9.3 billion in revenue in 2025 and has been the subject of thousands of hip replacement lawsuits.
Market Reaction
Johnson & Johnson (NYSE:JNJ) shares rose 1.3% to $268.96 in premarket trading on Monday after reports emerged that Apollo Global Management (NYSE:APO) is in discussions to acquire the healthcare group’s orthopedics business.
Deal Structure and Timing
According to a report from Bloomberg News on Friday that cited people familiar with the matter, the contemplated transaction could assign a value of nearly $20 billion to Johnson & Johnson’s orthopedics unit. The same report indicated that the parties could reach a definitive agreement within several weeks.
Orthopedics Unit Profile
The orthopedics division generated $9.3 billion in revenue in 2025. Despite its scale, the business has been dealing with extensive legal challenges, including thousands of lawsuits tied to its hip replacement devices.
Key Financial and Transaction Metrics
| Item | Detail |
|---|---|
| JNJ premarket share price | $268.96 |
| JNJ premarket move | +1.3% |
| Potential orthopedics unit valuation | Nearly $20 billion |
| Orthopedics unit revenue (2025) | $9.3 billion |
| Potential buyer | Apollo Global Management (NYSE:APO) |
| Estimated timing for possible agreement | Within several weeks (per report) |
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
